No Data
No Data
TD Cowen Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $185
HSBC Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $184
Market Technical Analysis: Will the US Stock Market's Rebound Ignite Your Next Trade?
Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival
Express News | Johnson & Johnson : HSBC Raises Target Price to $184 From $180
Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems 'Behind It'
loading...